ArticleJournal of acquired immune deficiency syndromes (1999)2019
Getting to Zero San Francisco: A Collective Impact Approach.
Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pooled it
- Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.The lancet. HIV · 2021Trial
- Article
- Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies.PLoS pathogens · 2025Article
- Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection.Journal of virology · 2025Article
- Gender and Intersecting Barriers and Facilitators to Access the HIV Cascade of Care in Manitoba, Canada, Before and During the COVID-19 Pandemic: A Qualitative Study.Tropical medicine and infectious disease · 2024Article
- Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease.Nature communications · 2024Article
- Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo.Global health & medicine · 2024Review
- Rapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease.medRxiv : the preprint server for health sciences · 2024Article
- Social, economic, and physical side effects impact PrEP uptake and persistence among transgender women in Peru.BMC public health · 2024Article
- Establishing evidence criteria for implementation strategies in the US: a Delphi study for HIV services.Implementation science : IS · 2024Article
- Continuing Low Awareness and Use of Pre-exposure Prophylaxis (PrEP) for HIV among People Who Inject Drugs (PWID), San Francisco, 2022.AIDS and behavior · 2024Article
- Interruptions in HIV and Behavioral Health Care for Criminal-Legal Involved People Living with HIV Following Implementation of Decarceration and Shelter in Place in San Francisco, California.AIDS and behavior · 2024Article
- Establishing Evidence Criteria for Implementation Strategies: A Delphi Study for HIV Services.Research square · 2024Article
- Time from treatment initiation to HIV viral suppression in public care facilities in Brazil: A nationwide linked databases cohort.PloS one · 2024Article
- Lived experiences with pre-exposure prophylaxis uptake and adherence among transgender women in Thailand: a qualitative study.Sexual health · 2024Article
- Sociodemographic and clinical follow-up profile of transgender people accessing pre-exposure prophylaxis for the risk of HIV transmission in São Paulo, Brazil (2018-2021).Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2024Article
- HIV Pre-Exposure Prophylaxis in Central and Eastern Europe-Gains and Challenges in An Ever-Changing World.Infectious diseases & clinical microbiology · 2022Review
- Effect of Social Determinants of Health on Uncontrolled Human Immunodeficiency Virus (HIV) Infection Among Persons With HIV in San Francisco, California.Open forum infectious diseases · 2022Article
- Improved PrEP Awareness and Use among Trans Women in San Francisco, California.AIDS and behavior · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBuilding on several decades of innovative HIV prevention and treatment programming in San Francisco, in 2014, a small group of academic, civic, and community leaders launched Getting to Zero San Francisco, a city-wide consortium focused on getting to zero HIV infections, zero HIV-related deaths, and zero HIV stigma and discrimination.
settingSan Francisco city and county.
methodsThe consortium operates under the principles of collective impact composed of 5 components: a common agenda, shared measurement, mutually reinforcing activities, continuous communication, and organization backbone. Two flagship initiatives are described: citywide scale-up of pre-exposure prophylaxis and rapid antiretroviral therapy upon diagnosis.
resultsThe number of new HIV diagnoses declined by over 50% from 399 to 197 from 2013 to 2018; the time from diagnosis to viral suppression decreased from 134 to 62 days during that period. However, continued racial/ethnic disparities in new HIV diagnoses and viral suppression rates point to the need for the Getting to Zero San Francisco committees to focus on racial/ethnic equity as a primary focus. Cisgender and transgender women, people who inject drugs, and people who are homeless also have lower viral suppression rates; ongoing initiatives are attempting to address these disparities.
conclusionA collective impact implementation strategy that operates by unifying municipal organizations toward a common goal was associated with citywide gains in reducing new HIV diagnosis and time to viral suppression in San Francisco. Formal evaluation of this strategy will help elucidate under which conditions this approach is most likely to succeed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.